BACKGROUND Sleep difficulty is a common symptom of cannabis withdrawal, but little research has objectively measured sleep or explored the effects of hypnotic medication on sleep during cannabis withdrawal. METHODS Twenty daily cannabis users completed a within-subject crossover study. Participants alternated between periods of ad libitum cannabis use and short-term cannabis abstinence (3 day...

Zolpidem, an imidazopyridine hypnotic drug acting as a selective gamma-aminobutyric acid (GABA) type A agonist, has been reported to produce significant motor improvement in patients with Parkinson’s disease (PD). However, relevant reports are scarce. We report a patient with advanced PD who had had a unilateral pallidotomy, unilateral thalamotomy and bilateral deep brain stimulation (DBS) of t...

BACKGROUND While an association between zolpidem use and fracture and road accident was previously proposed, this study aimed to further explore the frequency and risk of a wide spectrum of injuries in subjects prescribed with zolpidem in Taiwan. METHODS We identified 77,036 subjects who received Zolpidem treatment between 2005 and 2007. We randomly selected 77,036 comparison subjects who wer...

Zolpidem is a nonbenzodiazepine GABA(A) receptor modulator that binds in vitro with high affinity to GABA(A) receptors expressing alpha(1) subunits but with relatively low affinity to receptors expressing alpha(2), alpha(3), and alpha(5) subunits. In the present study, it was investigated whether this subtype selectivity could be detected and quantified in vivo. Three doses (1.25, 5, and 25 mg)...

Eighteen healthy volunteers (10 men and 8 women) participated in a single-dose, double-blind, three-way crossover pharmacokinetic and pharmacodynamic study. Treatment conditions were 0.25 mg of triazolam, a full-agonist benzodiazepine ligand; 10 mg of zolpidem, an imidazopyridine having relative selectivity for the type 1 benzodiazepine receptor subtype; and placebo. Weight-normalized clearance...

INTRODUCTION We examined the efficacy of combination therapy with α1-blocker tamsulosin and hypnotic zolpidem in patients who had suffered from sleep disturbance associated with nocturia. MATERIAL AND METHODS A total of 35 patients diagnosed with nocturia with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) were studied. After treatment with tamsulosin for...

A novel, simple and economic reverse phase high performance liquid chromatography (RP-HPLC) Stability indicating method has been developed for the estimation of zolpidem tartrate in bulk and tablet dosage form with greater precision and accuracy. Separation was achieved on C18 column (250X4.6mm i.d.,5μm) in isocratic mode using methanol and acetonitrile in the ratio 50:50 (v/v) as mobile phase,...

Randomized, placebo-controlled trials have shown that eszopiclone, a newly available nonbenzodiazepine hypnotic, effectively treats the symptoms of insomnia. Its pharmacokinetic and pharmacodynamic parameters are similar to those of the other currently available nonbenzodiazepine hypnotics (i.e., zolpidem and zaleplon). The unique quality of eszopiclone lies in its product labeling. It is not r...

BACKGROUND Sibutramine is a weight loss agent recently withdrawn from the European market due to cardiovascular risk concerns. It was used for long-term obesity treatment. Zolpidem is a short acting hypnotic agent commonly used in the treatment of insomnia. A number of case reports describing psychotic reaction to sibutramine were reported in the literature. CASE REPORT We present a case of a...

Zolpidem is a drug that is easily attached to the GABA receptors in the brain. This property makes it very effective for tranquilizing as well as hypnagogia. According to the advantages of electrochemical analysis like high selectivity, high sensitivity, low concentration of analyte, cost-effective, portable and easy-to-use setup, they gained high amount of attention among scientists for determ...